Jaguar health to present at biotrinity 2023 conference's r&d spotlight on rare diseases

Presentation will cover jaguar and napo therapeutics' focus on development and commercialization of crofelemer for short bowel syndrome (sbs) and congenital diarrheal disorders (cdd) crofelemer has received orphan drug designation from the fda and the european medicines agency for both sbs and a specific genetic abnormality resulting in a cdd condition san franciso, ca / accesswire / march 2, 2023 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today announced that lisa conte, the company's founder, president, and ceo, is scheduled to present at the biotrinity 2023 conference in london on tuesday, april 25, 2023 during the r&d spotlight session on rare diseases. ms. conte is also chairman of the board of napo therapeutics, the corporation jaguar established in italy in 2021 with a mission to expand crofelemer access in europe for the treatment and management of targeted orphan and rare disease indications.
JAGX Ratings Summary
JAGX Quant Ranking